Federal Register Notice: FDA is rescheduling the Pulmonary-Allergy Drugs Advisory Committee meeting canceled 3/7 due to inclement weather. The panel will now meet 4/17, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss a GlaxoSmithKline NDA for Breo Ellipta (fluticasone furoate and vilanterol dry powder inhaler) for the long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease. Contact Cindy Hong, (301) 796-9001. To view this notice, click here.